[OCTAVE and OPERA: discordance in hypertension therapy?].
While ACE-inhibitors have proven their prognostic benefit in many hypertension studies, a new approach has been proposed by inhibiting neutral endopeptidase, which degrades natriuretic peptides. The combined inhibition of ACE and endopeptidase was named "vasopeptidase-inhibition" and tested in several trial. Though effective in lowering blood pressure, a superiority to ACE-inhibitors alone could not be shown. A potentially serious side effect was the increased incidence of angioneurotic edema, which led to a complete stop in the development of this pharmaceutical strategy.
Philipp
Sebastian
S
Franz-Volhard-Klinik, Charité Berlin, Germany.
Dietz
Rainer
R
Willenbrock
Roland
R
D000799:Angioedema / Q000209:etiology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects; D004338:Drug Combinations; D004656:Enalapril / Q000008:administration & dosage / Q000009:adverse effects; D010450:Endopeptidases / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D013841:Thiazepines / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004338:Drug Combinations; D011725:Pyridines; D013841:Thiazepines; C106266:omapatrilat; D004656:Enalapril; D010450:Endopeptidases